A double-blind, placebo-controlled, phase II study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with DSM-5 attention-deficit/hyperactivity disorder (ADHD)
CNS Drugs Mar 23, 2018
Wigal TL, et al. - The efficacy of mazindol CR was evaluated in adults with ADHD. Researchers recognized that in the treatment of adults with ADHD, mazindol CR was efficacious with a large effect size, and was well tolerated. Mild to moderate treatment-emergent adverse events were reported. These included dry mouth, headache, nausea, fatigue, increased heart rate, decreased appetite, somnolence, middle insomnia, and constipation.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
